Eli Lilly Invests $6.5 Billion in Texas Facility to Manufacture Obesity Pill

Eli Lilly; Texas facility; obesity pill; orforglipron; pharmaceutical manufacturing; API; AI automation; supply chain resilience; job creation

Lilly’s Mounjaro Shows Strong Results in Youth Type 2 Diabetes, Paving Way for Expansion

Mounjaro; tirzepatide; type 2 diabetes; children; adolescents; SURPASS-PEDS; A1C reduction; BMI reduction; clinical trial; Eli Lilly